EA202190244A2 - Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков - Google Patents

Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков

Info

Publication number
EA202190244A2
EA202190244A2 EA202190244A EA202190244A EA202190244A2 EA 202190244 A2 EA202190244 A2 EA 202190244A2 EA 202190244 A EA202190244 A EA 202190244A EA 202190244 A EA202190244 A EA 202190244A EA 202190244 A2 EA202190244 A2 EA 202190244A2
Authority
EA
Eurasian Patent Office
Prior art keywords
glycosylation
overexpression
modulation
recombinant proteins
path regulators
Prior art date
Application number
EA202190244A
Other languages
English (en)
Other versions
EA202190244A3 (ru
Inventor
Шивани Гупта
Сохие Канг
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53757626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202190244(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA202190244A2 publication Critical patent/EA202190244A2/ru
Publication of EA202190244A3 publication Critical patent/EA202190244A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01101—Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.101)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01094—Protein N-acetylglucosaminyltransferase (2.4.1.94)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01143—Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.143)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Предложены способы модуляции свойств культуры клеток, экспрессирующей необходимый белок. В различных вариантах реализации способы относятся к сверхэкспрессии белков, участвующих в пути N-гликозилирования.
EA202190244A 2014-01-29 2014-12-11 Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков EA202190244A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461933137P 2014-01-29 2014-01-29

Publications (2)

Publication Number Publication Date
EA202190244A2 true EA202190244A2 (ru) 2021-05-31
EA202190244A3 EA202190244A3 (ru) 2021-08-31

Family

ID=53757626

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190244A EA202190244A3 (ru) 2014-01-29 2014-12-11 Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
EA201691532A EA037565B1 (ru) 2014-01-29 2014-12-11 Способ снижения содержания высокоманнозных гликоформ рекомбинантного белка

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201691532A EA037565B1 (ru) 2014-01-29 2014-12-11 Способ снижения содержания высокоманнозных гликоформ рекомбинантного белка

Country Status (14)

Country Link
US (3) US10227627B2 (ru)
EP (1) EP3099806A1 (ru)
JP (4) JP6474420B2 (ru)
KR (3) KR102410393B1 (ru)
CN (2) CN113774084B (ru)
AU (3) AU2014380174B2 (ru)
BR (1) BR112016017606A2 (ru)
CA (1) CA2938079C (ru)
CL (1) CL2016001900A1 (ru)
EA (2) EA202190244A3 (ru)
IL (3) IL282517B (ru)
MX (2) MX2016009911A (ru)
SG (1) SG10201912081RA (ru)
WO (1) WO2015116315A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
SG11201908328XA (en) * 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
BR112023021867A2 (pt) 2021-04-23 2023-12-19 Amgen Inc Composições de anticorpo anti-tslp e seus usos
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用
WO2024092064A1 (en) 2022-10-26 2024-05-02 Amgen Inc. Anti-tslp antibody compositions and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8206981B2 (en) 2004-03-05 2012-06-26 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
JP5017116B2 (ja) 2004-09-24 2012-09-05 アムジエン・インコーポレーテツド 修飾Ｆｃ分子
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
TW201028431A (en) 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
KR20110139292A (ko) * 2009-04-20 2011-12-28 화이자 인코포레이티드 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
ES2602108T3 (es) * 2010-04-07 2017-02-17 Momenta Pharmaceuticals, Inc. Método para cuantificar glicoformas que contienen alta manosa
TW201209160A (en) * 2010-04-27 2012-03-01 Lonza Ag Improved glycosylation of proteins in host cells
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production

Also Published As

Publication number Publication date
EA202190244A3 (ru) 2021-08-31
JP2022068365A (ja) 2022-05-09
KR102519540B1 (ko) 2023-04-10
IL270861A (en) 2020-01-30
CA2938079C (en) 2022-10-11
EA201691532A1 (ru) 2017-01-30
US20190010532A1 (en) 2019-01-10
US20200277642A1 (en) 2020-09-03
AU2018264100B2 (en) 2020-07-23
EA037565B1 (ru) 2021-04-14
AU2020239681A1 (en) 2020-10-15
IL246914A0 (en) 2016-09-29
CN106170554B (zh) 2021-08-17
JP2021040638A (ja) 2021-03-18
JP2017505620A (ja) 2017-02-23
AU2014380174B2 (en) 2018-08-30
MX2020012356A (es) 2021-01-29
MX2016009911A (es) 2016-10-28
US20190153496A1 (en) 2019-05-23
WO2015116315A1 (en) 2015-08-06
CN106170554A (zh) 2016-11-30
US10227627B2 (en) 2019-03-12
JP6797950B2 (ja) 2020-12-09
AU2014380174A1 (en) 2016-08-11
IL246914B (en) 2019-12-31
US10655156B2 (en) 2020-05-19
JP6474420B2 (ja) 2019-02-27
IL270861B (en) 2021-05-31
IL282517A (en) 2021-06-30
CN113774084B (zh) 2024-04-16
KR102410393B1 (ko) 2022-06-16
JP2019088305A (ja) 2019-06-13
KR20210114549A (ko) 2021-09-23
AU2018264100A1 (en) 2018-12-06
SG10201912081RA (en) 2020-02-27
KR20220086703A (ko) 2022-06-23
KR102301034B1 (ko) 2021-09-13
KR20160111943A (ko) 2016-09-27
EP3099806A1 (en) 2016-12-07
CN113774084A (zh) 2021-12-10
CL2016001900A1 (es) 2017-05-12
US10907186B2 (en) 2021-02-02
BR112016017606A2 (pt) 2017-10-10
CA2938079A1 (en) 2015-08-06
JP7034236B2 (ja) 2022-03-11
AU2020239681B2 (en) 2022-06-23
IL282517B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
EA202190244A2 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
MX2022000302A (es) Moleculas de union que inhiben el crecimiento del cancer.
MX2017006127A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
UY34885A (es) Proteínas de unión anti-mesotelina
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201791223A1 (ru) Процесс для управления уровнем содержания гликанов гликопротеина
UY34254A (es) Proteínas y péptidos modificados.
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
CY1120824T1 (el) Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
WO2014140927A3 (en) Proteins with modified glycosylation and methods of production thereof
EA201791918A1 (ru) Модификация белков клеток-хозяев
TW201613631A (en) Ghrelin secretion promoter
IL280553A (en) Cell culture strategies for modulating protein glycosylation
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
EA202191909A1 (ru) Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins
MX2016015615A (es) Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores.
NZ731491A (en) Cd83 binding proteins and uses thereof